December 28th, 2018

Allgenesis Biotherapeutics Inc., a Taiwan based specialty pharmaceutical company focused on developing novel ophthalmologic drugs, announced that it received U.S. patent covering multi-tyrosine kinase inhibitor in ophthalmic suspension for pterygium treatment.

“Allgenesis continues to explore treatment of other ocular surface diseases using Nintedanib in either micro- or nano-suspension for other 505(B)2 projects in its development pipeline and this patent marks our first major success to our IP protection portfolio in the U.S.,” said Dr. Madhu Cherukury, Chief Executive Officer of Allgenesis Biotherapeutics Inc. “With our pterygium multi-centered clinical trial ongoing, we are taking every step to strengthen our IP position in that field.

The newly issued patent provides with coverage of Multi-Tyrosine Kinase Inhibitor in ophthalmic suspension and its use to treat pterygium up to 2036.

About Allgenesis

Allgenesis is a clinical stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, wAMD, and other retinal diseases. AG-73305 is in the CMC stage of the development with IND filing before 1Q2021. AG-86893, a drug for the treatment of Pterygium or better-known as surfer’s eye, is in Phase 2a clinical trial in Australia with FPE in 4Q2018.

About AG-86893

AG-86893 is a topical ocular eye drop reformulation of a marketed oral drug, a multi-tyrosine kinase inhibitor targeting receptors of growth factors such as VEGF, PDGF and FGF. AG-86893 is being developed for the treatment of pterygium, following a 505(B)(2) pathway. Currently, there is no approved treatment for pterygium other than surgery. Clinical Phase 2a trial for AG-86893 is being conducted for pterygium patients in Australia with FPE in 4Q2018.